Skip to main content

Moderna, Inc. total debt

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026

Moderna, Inc.'s total debt was $670 million for fiscal year 2025 (the twelve months to 31 Dec 2025), down 2.2% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was $3.61 billion, up 392% from a year earlier.

From Moderna, Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.

Fiscal 2025
$670M
−2.2%
Q3 FY2026
$3.61B
+392% on a year

Total debt by fiscal year

—FY 2016—FY 2017$0FY 2018$136MFY 2019$238MFY 2020+74.8%$916MFY 2021+286%$1.20BFY 2022+31.0%$1.24BFY 2023+3.6%$685MFY 2024−44.9%$670MFY 2025−2.2%

Change on the year before, under each year. From FY 2018 to FY 2025, Moderna, Inc.'s total debt went from $0 to $670 million; the highest was $1.24 billion in FY 2023.

Moderna, Inc. total debt, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Total debt——$0$136M$238M$916M$1.20B$1.24B$685M$670M
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Total debt by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Moderna, Inc. total debt, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Total debt$685M$745M$741M$734M$670M$1.25B$1.25B$3.61B
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How total debt is measured

Total debt is the company's borrowings at the end of the period: short-term and long-term debt, including the current portion of long-term debt and finance leases. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Moderna, Inc.'s other figures

Total debt of comparable companies

Everything on MRNA, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.